胶原蛋白肽对关节疼痛的作用:为期6个月的随机双盲空白组对照临床测试(中英)

15 浏览
目的:患有上下肢或腰脊柱关节疼痛的主体连续6个月每天服用1200克含胶原蛋白的营养补充食物后的效用和安全性的评估。  设计:在相同组别进行对比性的双盲,随意性的多中心测试。  设置:用直观模拟标度尺评估年龄不少于50岁的200名男女患有关节疼痛的病人。  干涉:6个月期间让参与者每天服用1200克的水解胶原蛋白或安慰剂。  主要测量结果:6个月研究后,我们对比了活跃使用水解胶原蛋白组和安慰剂组之间的临床反映百分比系数。回应主体通过使用直观模拟标尺来确定承受最多关节疼痛的主体在临床上感受到最显著的改善(减少至少20%)。所有分析基于病人意向性治疗步骤进行。  结果:在第6个月,根据直观模拟标尺的数据,服用水解胶原蛋白临床回应者(51.6%)的比例明显地比安慰剂组(36.5%)别高。然而,在第3个月两组之间区别并不明显。通过观察,两组在安全和耐药性方面没有明显区别。  结论:此研究建议每天服用1200克水解胶原蛋白有助增加临床回应者的数量(根据直观模拟标度尺数据,至少提高了20%)。我们需要更多的研究来证实这种营养补充食物的临床效用。

Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study  OBJECTIVE:Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine.  DESIGN:Comparative double-blind randomized multicenter study in parallel groups.  SETTING:200 patients of both genders of at least 50 years old with joint pain assessed as 30 mm on a visual analogical scale (VAS).  INTERVENTION:Collagen hydrolysate 1200 mg/day or placebo during 6 months.  MAIN OUTCOME MEASURE:Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-to-treat procedure.  RESULTS:At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p<0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p=0.53). No significant difference in terms of security and tolerability was observed between the two groups.  CONCLUSIONS:This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement. 

来源:www.collagenli.com
这里已调用系统的信息评论模块,无需修改!
这里已调用系统的评论列表模块,无需修改!

联系我们

contact us
厦门市湖里区双鲤新城安兜北里38-1102室
0592-3592516/18106088899
0592 3592520
athena_fj@163.com